CMS: We’re ready to accept and process ICD-10 claims
The Centers for Medicare and Medicaid Services says it completed its final Medicare fee-for-service end-to-end testing... More
Dr. Brad Zebrack
WASHINGTON – Chalk up one for the little guy: Community cancer programs are better equipped for delivering psychosocial... More
ACOs generate savings, but few get bonuses
Accountable care organizations (ACOs) accounted for savings of more than $411 million in 2014, according to the Centers... More
Recurrence score assay driving chemo decisions in unexpected ways
Adoption of the 21-gene recurrence score (RS) assay does not appear to have decreased chemotherapy use overall among... More
Dr. Mikkael Sekeres
Cancer patients who arrive in the emergency department with febrile neutropenia (FN) received antibiotics much more... More
Fewer moles linked with more aggressive melanoma
NEW YORK – Consistent with another recently published report but counterintuitive, patients with a high number of nevi... More
Persistent mutations linked to poorer outcomes in AML
Persistent leukemia-associated mutations that can be detected in at least 5% of bone marrow cells at 30 days after... More
Mixed results for cancer survivorship care plan
A cancer survivorship care plan increased the information patients received yet failed to increase patient satisfaction... More
Bone marrow smear from a patient with acute myelomonocytic leukemia.
Clinical outcomes were significantly worse among younger patients with secondary and therapy-related acute myeloid... More
Lenalidomide + rituximab combo effective in recurrent follicular lymphoma
The combination of lenalidomide and rituximab was more active in patients with recurrent follicular lymphoma, compared... More
Secondary CNS lymphoma regimen linked to 41% survival at 5 years
Treatment with high doses of antimetabolites followed by rituximab plus high-dose sequential chemoimmunotherapy and... More
Dr. Antonio Subtil
NEW YORK – Both dermatologists and pathologists can make the mistake of diagnosing a long list of pseudolymphomas as... More
Aspirin, weight loss cut colorectal cancer risk in Lynch syndrome
Losing weight and taking aspirin protect people who are genetically predisposed to colorectal cancer from developing... More
CDC: Chinese study highlights need for smoke-free policies
Strictly enforced tobacco control regulations are necessary to effectively protect the public from the dangers of... More
Reduced invasive recurrence after DCIS does not reduce mortality
Radiotherapy after breast-conserving surgery for ductal carcinoma in situ reduces the risk of ipsilateral invasive... More
Vemurafenib looks promising for several nonmelanoma malignancies
Vemurafenib showed promising activity against several nonmelanoma cancers carrying BRAF V600 mutations in a preliminary... More

Reviews

Marco Ruiz et al
Lung cancer is one of the most common malignancies in HIV-infected patients. Prevalence and mortality outcomes are higher in HIV-infected populations than in noninfected patients. There are several oral agents available for patients who harbor specif... More »
 

Reviews

Ruben Guzman-Marin et al
Sleep disturbances are common among patients with cancer for many reasons. Sleep problems can be present at any stage during treatment for cancer and in some patients, sleep disturbance may be the presenting symptoms that lead to the diagnosis of som... More »
 
Shaun Hanson et al
Background Treatment outcomes for non-small-cell lung cancer (NSCLC) patients diagnosed at stage IIIA have been analyzed in many studies, which generally involve patients younger and healthier than the average patient with this disease. Objective To... More »
 
Bart Frizzell et al
Background and objective Our group created and routinely reviewed a dedicated prostate intensity-modulated radiation therapy (IMRT) delivery program. Previously, a retrospective review of our experience demonstrated that a larger bladder volume reduc... More »
 

Features

Jane de Lartigue
Historically, cancer has been diagnosed and treated on the basis of the tissue of origin. The promise of personalized therapy, matched more precisely to an individual’s tumor, was ushered in with the development of molecularly targeted therapies, b... More »
 

Features

Susan London, Neil Osterweil, Patrice Wendling
Immunotherapies once again took center stage at the 2015 annual meeting of the American Society for Clinical Oncology in Chicago, though many other groundbreaking clinical advances were also presented. The meeting’s theme, “Illumination and innov... More »
 

From the Editor

David Cella and Lynne Wagner
In the opinion of most, precision medicine is the future of cancer therapeutics. By producing response rates well into double digits, and substantially extending progression-free and overall survival, the molecular testing of tumors to select optimal... More »
 

From the Editor

Howard A Burris, III, MD
The 2015 annual meeting of the American Society for Clinical Oncology, themed “Illumination and innovation: transforming data into learning,” brought together more than 37,000 attendees in Chicago and featured numerous clinical advances that will... More »